Welcome to our dedicated page for Merit Med Sys news (Ticker: MMSI), a resource for investors and traders seeking the latest updates and insights on Merit Med Sys stock.
Merit Medical Systems Inc. develops, manufactures and distributes proprietary medical devices used in interventional, diagnostic and therapeutic procedures, with product activity concentrated in cardiology, radiology, oncology, critical care and endoscopy. Company news commonly covers operating results, annual guidance, revenue presentation by Foundational and Therapeutic product categories, and portfolio actions involving acquired or divested device lines.
Recurring updates also include commercial launches and distribution arrangements for products such as the Resilience Through-the-Scope Esophageal Stent, ViaVerte basivertebral nerve ablation system, OneMark Detection Imaging System and OneMark Tissue Markers. Governance announcements and healthcare conference participation appear alongside financial and product disclosures.
Merit Medical Systems (NASDAQ: MMSI) announced on May 26, 2020, that it has received the CE mark for its WRAPSODY™ Endovascular Stent Graft System from the British Standards Institution (BSI). This device aims to treat stenosis or occlusion in hemodialysis patients and is set to be introduced in Europe as procedures resume post-COVID-19. Merit has worked on this product for nearly eight years and recently completed the WRAPSODY FIRST study with 46 patients. The company also submitted an IDE application to the FDA for its upcoming WAVE Pivotal Study.